4-(chloromethyl)-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one | 911290-37-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 4-(chloromethyl)-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
• 英文别名: 4-(Chloromethyl)-7-[(3-fluorophenyl)methoxy]chromen-2-one
• CAS: 911290-37-4
• 化学式: C₁₇H₁₂ClFO₃
• 分子量: 318.732
• InChiKey: AHIYZZWJCBEKJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(chloromethyl)-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one 、 1-(2-aminoethyl)-3-(benzyloxy)-2-methylpyridin-4(1H)-one 在 potassium carbonate 、 potassium iodide 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Design, synthesis and biological evaluation of potential anti-AD hybrids with monoamine oxidase B inhibitory and iron-chelating effects

  摘要：

  DOI：

  10.1016/j.bioorg.2020.104564
• 作为产物：
  描述：

  间苯二酚 在 硫酸 、 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 生成 4-(chloromethyl)-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
  参考文献：
  名称：

  追逐 ChEs-MAO B 多靶点 4-氨甲基-7-苄氧基-2H-Chromen-2-酮

  摘要：

  研究了一系列 4-氨甲基-7-苄氧基-2H-色烯-2-酮，旨在鉴定多种胆碱酯酶（乙酰基和丁酰基、AChE 和 BChE）和单胺氧化酶 B (MAO B) 的潜在抑制剂抗阿尔茨海默病分子。从先前报道的有效 MAO B 抑制剂 (3) 开始，我们研究了苄氧基或碱性部分的单点修饰。体外筛选突出显示了三效化合物 (6、8、9、16、20)，显示出纳摩尔级选择性 MAO B 抑制作用以及低微摩尔水平下针对 ChE 的 IC50 值。对 AChE 进行酶动力学分析并对目标酶进行对接模拟，以深入了解作用机制和合理的结合模式。

  DOI：

  10.3390/molecules24244507

文献信息

• Design, Synthesis, and Biological Evaluation of Imidazolyl Derivatives of 4,7-Disubstituted Coumarins as Aromatase Inhibitors Selective over 17-α-Hydroxylase/C17−20 Lyase
  作者：Angela Stefanachi、Angelo D. Favia、Orazio Nicolotti、Francesco Leonetti、Leonardo Pisani、Marco Catto、Christina Zimmer、Rolf W. Hartmann、Angelo Carotti

  DOI：10.1021/jm101120u

  日期：2011.3.24

  The design, synthesis, and biological evaluation of a series of new aromatase (AR, CYP19) inhibitors bearing an imidazole ring linked to a 7-substituted coumarin scaffold at position 4 (or 3) are reported. Many compounds exhibited an aromatase inhibitory potency in the nanomolar range along with a high selectivity over 17-α-hydroxylase/C17−20 lyase (CYP17). The most potent AR inhibitor was the 7-(3

  报道了一系列新的芳香酶（AR，CYP19）抑制剂的设计，合成和生物学评估，这些抑制剂带有与7位取代的香豆素骨架连接的4位（或3位）咪唑环。许多化合物在纳摩尔浓度范围内均显示出芳香化酶抑制潜能，并且对17-α-羟化酶/ C17-20裂解酶（CYP17）具有较高的选择性。最有效的AR抑制剂是7-（3,4-二氟苯氧基）-4-咪唑基甲基香豆素24，IC 50 = 47 nM。在一定数量的香豆素衍生物上的对接模拟可以识别驱动结合的最重要的相互作用，并清楚地表明香豆素和紧密相关的杂环分子支架的适当结构修饰的允许和不允许的区域。
• Chasing ChEs-MAO B Multi-Targeting 4-Aminomethyl-7-Benzyloxy-2H-Chromen-2-ones
  作者：Mariagrazia Rullo、Marco Catto、Antonio Carrieri、Modesto de Candia、Cosimo Damiano Altomare、Leonardo Pisani

  DOI：10.3390/molecules24244507

  日期：——

  multiple inhibitors of cholinesterases (acetyl- and butyryl-, AChE and BChE) and monoamine oxidase B (MAO B) as potential anti-Alzheimer molecules. Starting from a previously reported potent MAO B inhibitor (3), we studied single-point modifications at the benzyloxy or at the basic moiety. The in vitro screening highlighted triple-acting compounds (6, 8, 9, 16, 20) showing nanomolar and selective MAO B inhibition

  研究了一系列 4-氨甲基-7-苄氧基-2H-色烯-2-酮，旨在鉴定多种胆碱酯酶（乙酰基和丁酰基、AChE 和 BChE）和单胺氧化酶 B (MAO B) 的潜在抑制剂抗阿尔茨海默病分子。从先前报道的有效 MAO B 抑制剂 (3) 开始，我们研究了苄氧基或碱性部分的单点修饰。体外筛选突出显示了三效化合物 (6、8、9、16、20)，显示出纳摩尔级选择性 MAO B 抑制作用以及低微摩尔水平下针对 ChE 的 IC50 值。对 AChE 进行酶动力学分析并对目标酶进行对接模拟，以深入了解作用机制和合理的结合模式。
• Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives
  申请人：Carotti Angelo

  公开号：US20090005436A1

  公开（公告）日：2009-01-01

  This invention is related to novel aminoalkyl- and amidoalkyl-benzopyran derivatives of the following general formula (I) wherein: the group is a substituent in position 6 or 7 wherein: R is an aromatic mono- or bi-cyclic carbocyclic ring or a mono- or bi-cyclic heterocyclic ring radical, said rings being optionally substituted by one or two substituents selected from (C 1 -C 5 ) straight or branched alkyl, (C 1 -C 5 ) straight or branched alkoxy, hydroxy, halogen and trifluoromethyl; m is zero or an integer from 1 to 3; n, p, R 1 and R 2 are as herein indicated and R 3 and R 4 are both hydrogen or taken together represent an oxygen atom, and the pharmaceutically acceptable salts thereof. The compounds that are active as selective and reversible MAO-B inhibitors in vitro and in vivo, are useful as medicaments for the prevention and the treatment of CNS degenerative disorders.

  本发明涉及以下通式（I）的新型氨基烷基和酰胺烷基苯并吡喃衍生物： 其中：基团是6或7位的取代基，其中：R是芳香单环或双环碳环或单环或双环杂环基团，所述环可以选择地由一或两个取代基取代，所述取代基选择自（C1-C5）直链或支链烷基，（C1-C5）直链或支链烷氧基，羟基，卤素和三氟甲基；m为零或1至3的整数；n、p、R1和R2如本文所示，而R3和R4均为氢或一起代表氧原子，以及其药学上可接受的盐。 这些化合物在体外和体内作为选择性和可逆的MAO-B抑制剂具有活性，可用作预防和治疗中枢神经系统退行性疾病的药物。
• Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2<i>H</i>-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor
  作者：Leonardo Pisani、Giovanni Muncipinto、Teresa Fabiola Miscioscia、Orazio Nicolotti、Francesco Leonetti、Marco Catto、Carla Caccia、Patricia Salvati、Ramon Soto-Otero、Estefania Mendez-Alvarez、Celine Passeleu、Angelo Carotti

  DOI：10.1021/jm9010127

  日期：2009.11.12

  In an effort to discover novel selective monoamine oxidase (MAO) B inhibitors with favorable physicochemical and pharmacokinetic profiles, 7-[m-halogeno)benzyloxy]coumarins bearing properly selected polar substituents at position 4 were designed, synthesized, and evaluated as MAO inhibitors. Several compounds with MAO-B inhibitory activity in the nanomolar range and excellent MAO-B selectivity (selectivity index SI > 400) were identified. Structure-affinity relationships and docking simulations provided valuable insights into the enzyme-inhibitor binding interactions at position 4, which has been poorly explored. Furthermore, computational and experimental studies led to the identification and biopharmacological characterization of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate 22b (NW-1772) as an in vitro and in vivo potent and selective MAO-B inhibitor, with rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, slight inhibition of selected cytochrome P450s, and low in vitro toxicity. On the basis of this preliminary preclinical profile, inhibitor 22b might be viewed as a promising clinical candidate for the treatment of neurodegenerative diseases.
• Design, synthesis and biological evaluation of potential anti-AD hybrids with monoamine oxidase B inhibitory and iron-chelating effects
  作者：Jianan Guo、Zhisheng Mi、Xiaoying Jiang、Changjun Zhang、Zili Guo、Linzi Li、Jinping Gu、Tao Zhou、Renren Bai、Yuanyuan Xie

  DOI：10.1016/j.bioorg.2020.104564

  日期：2021.3